Search Close


Scancell to Present at Upcoming Scientific Conference

12th September 2014

Scancell Holdings plc, (‘Scancell’ or the ‘Company’) the developer of novel immunotherapies for the treatment of cancer, announces that Professor Lindy Durrant, Joint CEO of Scancell, is scheduled to present on SCIB1, the Company’s clinical stage ImmunoBody® vaccine for the treatment of melanoma, and the ImmunoBody® technology platform at the following conferences:




 3rd Annual Cancer Vaccines Conference,  London, UK (15-16 September 2014)

 Phase I/II trial of a novel  antibody DNA immunotherapy,  SCIB1 ImmunoBody® which  targets CD64, in the treatment of  melanoma

 15 September 2014 at 15.20

 Cancer Antibodies Vaccines/Adjuvants &  Delivery Conference (CAVAD 14), Lausanne,  Switzerland (17-19 September 2014)

 Phase I/II trial of a novel  antibody DNA immunotherapy,  targeting CD64, in the treatment  of melanoma

 17 September 2014 at 11.30

 14th International Conference on Progress  in Vaccination Against Cancer (PIVAC-14),  Rome, Italy (24-26 September 2014)

 Phase 1/2 clinical trial of SCIB1  ImmunoBody® in stage III/IV  melanoma


Professor Lindy Durrant will also be on the Scientific Advisory Panel and conference co-chair at CAVAD 14.

For Further Information:

Dr Richard Goodfellow, Joint CEO

Professor Lindy Durrant, Joint CEO

Scancell Holdings Plc

Scancell Holdings Plc

+ 44 (0) 74 2323 0 497

Mo Noonan/Simon Conway

FTI Consulting

+ 44 (0) 20 3727 1000

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1 has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects.

Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic Tlymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

Webcasts, Interviews and Media Coverage

Scancell Holdings lays groundwork for pivotal year

A £3.9mln injection from the life sciences fund Vulpes will effectively bankroll the latest R&D

Tue, 20 Aug 2019 06:05:00

Scancell to begin UK arm of phase II skin cancer trial ‘immediately’

Discussions with US regulators have taken longer than expected, so Scancell will now focus its efforts on completing the UK arm of the trial before re-submitting its US application at a later date

Mon, 19 Aug 2019 06:46:00